scispace - formally typeset
A

Allan Bradley

Researcher at Wellcome Trust Sanger Institute

Publications -  385
Citations -  81969

Allan Bradley is an academic researcher from Wellcome Trust Sanger Institute. The author has contributed to research in topics: Gene & Genome. The author has an hindex of 127, co-authored 379 publications receiving 77492 citations. Previous affiliations of Allan Bradley include Howard Hughes Medical Institute & University of Texas MD Anderson Cancer Center.

Papers
More filters
Journal ArticleDOI

Investigation of coelectroporation as a method for introducing small mutations into embryonic stem cells.

TL;DR: Investigation of coelectroporation as a method for introducing minor genetic changes into specific genes in embryonic stem cells found that 3 of 36 of the 6-TG-resistant clones had the desired 4-bp insertion without any other disruption of the HPRT locus.
Book ChapterDOI

Genetic manipulation of the mouse via gene targeting in embryonic stem cells.

TL;DR: Two cell lines that can be routinely transmitted through the germline of chimeras after cloning and prolonged selection in tissue culture are developed and a variety of methods for generating non-selected mutations at the X-linked hprt locus in ES cells are established.
Book ChapterDOI

Genome-wide forward genetic screens in mouse ES cells.

TL;DR: The principles underpinning genetic screens in mouse ES cells with examples of previously successful screens are described and protocols are provided for piggyBac transposon-mediated mutagenesis, production of the corresponding homozygous mutants in a Blm-deficient genetic background, and methods for mapping and validation of mutations recovered from screens of such libraries.
Journal ArticleDOI

Isolation of homozygous mutant mouse embryonic stem cells using a dual selection system

TL;DR: This method can provide homozygous mammalian loss-of-function mutants for forward genetic applications by constructing DNA vectors that are selectable based on their copy number and using the piggyBac transposon to limit the initial mutagenesis to one copy per cell.
Patent

Tumor susceptible non-human animals

TL;DR: In this article, a desired non-human animal or an animal cell or human cell which contains a predefined, specific and desired alteration in at least one of its two p53 chromosomal alleles, such that one of these alleles contains a mutation which alters the expression of the allele, and the other of the alleles expresses either a normal p53 gene product, or comprises an identical or different p53 mutation.